Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE.

Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37. doi: 10.1016/j.addr.2009.03.009. Epub 2009 Apr 17. Review.

2.

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE.

Mol Pharm. 2008 Jul-Aug;5(4):487-95. doi: 10.1021/mp800032f. Epub 2008 May 30. Review.

3.

The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior.

Gao H, He Q.

Expert Opin Drug Deliv. 2014 Mar;11(3):409-20. doi: 10.1517/17425247.2014.877442. Epub 2014 Jan 8. Review.

PMID:
24397260
4.

Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems.

Karmali PP, Simberg D.

Expert Opin Drug Deliv. 2011 Mar;8(3):343-57. doi: 10.1517/17425247.2011.554818. Epub 2011 Feb 4. Review.

PMID:
21291354
5.

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Alexis F, Pridgen E, Molnar LK, Farokhzad OC.

Mol Pharm. 2008 Jul-Aug;5(4):505-15. doi: 10.1021/mp800051m. Epub 2008 Aug 4. Review.

6.

Disposition of nanoparticle-based delivery system via inner ear administration.

Chen G, Zhang X, Yang F, Mu L.

Curr Drug Metab. 2010 Dec;11(10):886-97. Review.

PMID:
21208174
7.

Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking.

Duan X, Li Y.

Small. 2013 May 27;9(9-10):1521-32. doi: 10.1002/smll.201201390. Epub 2012 Sep 28. Review.

PMID:
23019091
8.

Towards understanding of nanoparticle-protein corona.

Ge C, Tian J, Zhao Y, Chen C, Zhou R, Chai Z.

Arch Toxicol. 2015 Apr;89(4):519-39. doi: 10.1007/s00204-015-1458-0. Epub 2015 Jan 31. Review.

PMID:
25637415
9.

Nanoparticles and microparticles for skin drug delivery.

Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS.

Adv Drug Deliv Rev. 2011 May 30;63(6):470-91. doi: 10.1016/j.addr.2011.01.012. Epub 2011 Feb 23. Review.

PMID:
21315122
10.

Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies.

Khlebtsov N, Dykman L.

Chem Soc Rev. 2011 Mar;40(3):1647-71. doi: 10.1039/c0cs00018c. Epub 2010 Nov 16. Review.

PMID:
21082078
11.

Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle.

Saptarshi SR, Duschl A, Lopata AL.

J Nanobiotechnology. 2013 Jul 19;11:26. doi: 10.1186/1477-3155-11-26. Review.

12.

Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment.

Walkey CD, Chan WC.

Chem Soc Rev. 2012 Apr 7;41(7):2780-99. doi: 10.1039/c1cs15233e. Epub 2011 Nov 15. Review.

PMID:
22086677
13.

Theranostic nanoparticles engineered for clinic and pharmaceutics.

Ma X, Zhao Y, Liang XJ.

Acc Chem Res. 2011 Oct 18;44(10):1114-22. doi: 10.1021/ar2000056. Epub 2011 Jul 6. Review.

PMID:
21732606
14.

Biological barriers and current strategies for modifying nanoparticle bioavailability.

Prantner AM, Scholler N.

J Nanosci Nanotechnol. 2014 Jan;14(1):115-25. Review.

PMID:
24730254
15.

Biomolecular coronas provide the biological identity of nanosized materials.

Monopoli MP, Aberg C, Salvati A, Dawson KA.

Nat Nanotechnol. 2012 Dec;7(12):779-86. doi: 10.1038/nnano.2012.207. Review.

PMID:
23212421
16.

Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery.

Yoo JW, Doshi N, Mitragotri S.

Adv Drug Deliv Rev. 2011 Nov;63(14-15):1247-56. doi: 10.1016/j.addr.2011.05.004. Epub 2011 May 13. Review.

PMID:
21605607
17.

Relating nanomaterial properties and microbial toxicity.

Suresh AK, Pelletier DA, Doktycz MJ.

Nanoscale. 2013 Jan 21;5(2):463-74. doi: 10.1039/c2nr32447d. Epub 2012 Dec 3. Review.

PMID:
23203029
18.

Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.

Moghimi SM, Hunter AC, Andresen TL.

Annu Rev Pharmacol Toxicol. 2012;52:481-503. doi: 10.1146/annurev-pharmtox-010611-134623. Epub 2011 Oct 24. Review.

PMID:
22035254
19.

Engineering strategies to enhance nanoparticle-mediated oral delivery.

Yamanaka YJ, Leong KW.

J Biomater Sci Polym Ed. 2008;19(12):1549-70. doi: 10.1163/156856208786440479. Review.

PMID:
19017470
20.

Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.

Gaumet M, Vargas A, Gurny R, Delie F.

Eur J Pharm Biopharm. 2008 May;69(1):1-9. Epub 2007 Aug 7. Review.

PMID:
17826969
Items per page

Supplemental Content

Write to the Help Desk